ELI LILLY AND COMPANY

NYSE: LLY (Eli Lilly and Company)

Kemas kini terakhir: 5 hari lalu, 1:00PM

795.35

7.16 (0.91%)

  • 1H 0.91%
  • 5H 6.33%
  • 1B -1.34%
  • 6B -4.47%
  • Tahun Ke Tarikh 34.30%
  • 1T 35.80%
  • 5T 570.22%
Penutupan Terdahulu 788.19
Buka 791.33
Jumlah Dagangan 2,055,067
Purata Dagangan (3B) 3,599,157
Modal Pasaran 715,270,914,048
Harga / Pendapatan (P/E TTM) 85.52
Harga / Pendapatan (P/E Ke hadapan) 35.09
Harga / Jualan (P/S) 17.60
Harga / Buku (P/B) 50.23
Julat 52 Minggu
561.65 (-29%) — 972.53 (22%)
Tarikh Pendapatan 4 Feb 2025 - 10 Feb 2025
Hasil Dividen (DY TTM) 0.65%
Margin Keuntungan 20.48%
Margin Operasi (TTM) 39.77%
EPS Cair (TTM) 9.31
Pertumbuhan Hasil Suku Tahunan (YOY) 20.40%
Pertumbuhan Pendapatan Suku Tahunan (YOY) 68.30%
Jumlah Hutang/Ekuiti (D/E MRQ) 218.08%
Nisbah Semasa (MRQ) 1.27
Aliran Tunai Operasi (OCF TTM) 6.03 B
Aliran Tunai Bebas Leveraj (LFCF TTM) -1.31 B
Pulangan Atas Aset (ROA TTM) 13.95%
Pulangan Atas Ekuiti (ROE TTM) 65.32%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Drug Manufacturers - General (US) Bercampur Menaik
Drug Manufacturers - General (Global) Bercampur Menaik
Stok Eli Lilly and Company Menurun Menaik

AISkor Stockmoo

0.2
Konsensus Penganalisis 2.0
Aktiviti Orang Dalam 1.5
Volatiliti Harga 2.0
Purata Bergerak Teknikal -2.5
Osilator Teknikal -2.0
Purata 0.20

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
LLY 715 B 0.65% 85.52 50.23
NVS 217 B 3.57% 18.61 4.88
JNJ 362 B 3.26% 24.87 5.23
ABBV 360 B 3.09% 70.84 51.84
MRK 251 B 3.11% 20.75 5.72
PFE 143 B 6.66% 33.64 1.57

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Sektor Healthcare
Industri Drug Manufacturers - General
Gaya Pelaburan Large Growth
% Dimiliki oleh Orang Dalam 0.15%
% Dimiliki oleh Institusi 83.38%

Pemilikan

Nama Tarikh Syer Dipegang
Lilly Endowment Inc 30 Sep 2024 96,891,978
Pnc Financial Services Group, Inc. 30 Sep 2024 51,360,730
Julat 52 Minggu
561.65 (-29%) — 972.53 (22%)
Julat Harga Sasaran
885.00 (11%) — 1,250.00 (-99%)
Tinggi 1,250.00 (Citigroup, 57.16%) Beli
Median 1,033.00 (29.88%)
Rendah 885.00 (Cantor Fitzgerald, 11.27%) Beli
Purata 1,050.89 (32.13%)
Jumlah 9 Beli
Harga Purata @ Panggilan 864.40
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
Wolfe Research 15 Nov 2024 1,000.00 (25.73%) Beli 746.20
Deutsche Bank 04 Nov 2024 1,015.00 (27.62%) Beli 806.14
03 Oct 2024 1,025.00 (28.87%) Beli 885.55
B of A Securities 31 Oct 2024 1,100.00 (38.30%) Beli 829.74
Barclays 31 Oct 2024 975.00 (22.59%) Beli 829.74
Citigroup 25 Oct 2024 1,250.00 (57.16%) Beli 892.70
13 Sep 2024 1,060.00 (33.27%) Beli 923.71
Bernstein 17 Oct 2024 1,100.00 (38.30%) Beli 917.12
Truist Securities 10 Oct 2024 1,033.00 (29.88%) Beli 910.69
Cantor Fitzgerald 16 Sep 2024 885.00 (11.27%) Beli 923.54
09 Sep 2024 885.00 (11.27%) Beli 908.27
JP Morgan 13 Sep 2024 1,100.00 (38.30%) Beli 923.71
Papar semua

Tiada data dalam julat masa ini.

  • 3M
Tarikh Jenis Butiran
04 Dec 2024 CNBC Eli Lilly's Zepbound causes greater weight loss than Novo Nordisk's Wegovy in head-to-head trial
04 Dec 2024 Pengumuman Lilly's Zepbound® (tirzepatide) superior to Wegovy® (semaglutide) in head-to-head trial showing an average weight loss of 20.2% vs. 13.7%
26 Nov 2024 CNBC Amgen says obesity drug caused up to 20% weight loss after a year, with no plateau
19 Nov 2024 Pengumuman Lilly announces changes on board of directors
18 Nov 2024 Pengumuman Lilly's muvalaplin lowered lipoprotein(a) levels in adults with high risk for cardiovascular events by up to 85% at highest tested dose
16 Nov 2024 Pengumuman Lilly's tirzepatide reduced the risk of worsening heart failure events by 38% in adults with heart failure with preserved ejection fraction (HFpEF) and obesity
13 Nov 2024 Pengumuman Treatment with tirzepatide in adults with pre-diabetes and obesity or overweight resulted in sustained weight loss and nearly 99% remained diabetes-free at 176 weeks
13 Nov 2024 CNBC Amgen says no concerns around weight loss drug’s bone density data after stock falls
05 Nov 2024 Pengumuman Lilly announces details of presentations at the 2024 American Society of Hematology (ASH) Annual Meeting
01 Nov 2024 Pengumuman Lilly to Present Results from Phase 3 EMBER-3 Study of Imlunestrant, an Oral SERD, and Additional Results from Its Breast Cancer Portfolio at the San Antonio Breast Cancer Symposium
30 Oct 2024 CNBC Novo Nordisk's Ozempic and Wegovy now available in the U.S. after shortages, FDA says
30 Oct 2024 CNBC Eli Lilly stock tumbles after drug giant misses estimates and slashes profit guidance
30 Oct 2024 CNBC Eli Lilly's Zepbound and Mounjaro are no longer in shortage. Here's where their sales still disappointed
30 Oct 2024 Pengumuman Lilly reports Q3 2024 financial results highlighted by strong volume-driven revenue growth from New Products
29 Oct 2024 Pengumuman Modified Titration of Donanemab Demonstrated Reduction of ARIA-E in Early Symptomatic Alzheimer's Disease Patients in Phase 3b study
28 Oct 2024 Pengumuman Lilly's mirikizumab is first and only IL23p19 antagonist to report long-term, multi-year, sustained efficacy and safety data for both ulcerative colitis and Crohn's disease
28 Oct 2024 Pengumuman Lilly declares fourth-quarter 2024 dividend
25 Oct 2024 Pengumuman Lilly's EBGLYSS™ (lebrikizumab-lbkz) demonstrated meaningful improvement in skin clearance and itch relief in the majority of patients with moderate-to-severe atopic dermatitis who discontinued dupilumab
23 Oct 2024 Pengumuman Lilly's Kisunla™ (donanemab-azbt) Receives Marketing Authorization in Great Britain for the Treatment of Mild Cognitive Impairment and Mild Dementia Due to Alzheimer's Disease in Adult Patients Who Are Apolipoprotein E Ε4 Heterozygotes or Non-Carriers
23 Oct 2024 CNBC Novo Nordisk asks FDA to ban compounding pharmacies from making Ozempic, Wegovy copies
16 Oct 2024 Pengumuman Survey reveals 8 in 10 Americans with ulcerative colitis struggle to find a public restroom during emergencies
16 Oct 2024 Pengumuman Lilly confirms date and conference call for third-quarter 2024 financial results announcement
14 Oct 2024 Pengumuman Lilly reports one-year histologic outcomes in Phase 3 study of mirikizumab compared to ustekinumab for Crohn's disease
02 Oct 2024 Pengumuman Lilly announces new $4.5 billion site - the Lilly Medicine Foundry - to drive innovation in drug production and make medicines for clinical trials
02 Oct 2024 CNBC Eli Lilly to build $4.5 billion research and manufacturing center to propel drug pipeline
25 Sep 2024 CNBC Novo Nordisk's diabetes drug Ozempic may lower the risk of opioid overdoses, study says
25 Sep 2024 Pengumuman New data show Lilly's EBGLYSS™ (lebrikizumab-lbkz) provided sustained disease control for up to three years in more than 80% of adults and adolescents with moderate-to-severe atopic dermatitis
24 Sep 2024 Pengumuman Lilly's Kisunla™ (donanemab-azbt) Approved in Japan for the Treatment of Early Symptomatic Alzheimer's Disease
24 Sep 2024 CNBC 'Stop ripping us off': Senate grills Novo Nordisk CEO on weight loss drug pricing
21 Sep 2024 CNBC FTC sues drug middlemen for allegedly inflating insulin prices
16 Sep 2024 CNBC Drugmakers bet billions that targeted radiation could become the next cancer breakthrough
13 Sep 2024 Pengumuman FDA Approves Lilly's EBGLYSS™ (lebrikizumab-lbkz) for Adults and Children 12 Years and Older with Moderate-to-Severe Atopic Dermatitis
12 Sep 2024 Pengumuman Lilly expands manufacturing footprint in Ireland with $1.8 billion investment
10 Sep 2024 Pengumuman Once-weekly dose of insulin efsitora alfa delivers A1C reduction consistent with the most advanced daily insulin in people with type 2 diabetes
10 Sep 2024 Pengumuman With once-a-week dosing, insulin efsitora alfa delivers similar A1C reduction compared to daily insulin in adults with type 1 diabetes
09 Sep 2024 Pengumuman Lilly appoints Lucas Montarce as executive vice president and chief financial officer
05 Sep 2024 Pengumuman In a first-of-its-kind fixed dose study, once weekly insulin efsitora alfa leads to A1C reduction similar to daily insulin
05 Sep 2024 TheFinance 3 US Blue-Chip Earnings Reports That You Should Not Miss
04 Sep 2024 Pengumuman Lilly and EVA Pharma collaborate to expand access to baricitinib in low- to middle-income countries
Papar semua
Hasil Dividen (DY TTM) 0.65%
Purata Hasil Dividen 5T 1.36%
Nisbah Pembayaran 54.20%
Jangkaan Pembayaran Dividen Seterusnya Sep 2025
Tarikh EX Tarikh Pengumuman Tarikh Pembayaran Perincian
15 Nov 2024 28 Oct 2024 10 Dec 2024 1.3 Tunai
15 Aug 2024 24 Jun 2024 10 Sep 2024 1.3 Tunai
15 May 2024 06 May 2024 10 Jun 2024 1.3 Tunai
14 Feb 2024 08 Dec 2023 08 Mar 2024 1.3 Tunai
14 Nov 2023 01 Nov 2023 08 Dec 2023 1.13 Tunai
14 Aug 2023 26 Jun 2023 08 Sep 2023 1.13 Tunai
12 May 2023 01 May 2023 09 Jun 2023 1.13 Tunai
14 Feb 2023 12 Dec 2022 10 Mar 2023 1.13 Tunai
14 Nov 2022 17 Oct 2022 09 Dec 2022 0.98 Tunai
12 Aug 2022 27 Jun 2022 09 Sep 2022 0.98 Tunai
13 May 2022 02 May 2022 10 Jun 2022 0.98 Tunai
14 Feb 2022 13 Dec 2021 10 Mar 2022 0.98 Tunai
12 Nov 2021 18 Oct 2021 10 Dec 2021 0.85 Tunai
12 Aug 2021 29 Jun 2021 10 Sep 2021 0.85 Tunai
13 May 2021 03 May 2021 10 Jun 2021 0.85 Tunai
11 Feb 2021 14 Dec 2020 10 Mar 2021 0.85 Tunai
12 Nov 2020 19 Oct 2020 10 Dec 2020 0.74 Tunai
13 Aug 2020 15 Jul 2020 10 Sep 2020 0.74 Tunai
14 May 2020 04 May 2020 10 Jun 2020 0.74 Tunai
13 Feb 2020 16 Dec 2019 10 Mar 2020 0.74 Tunai
14 Nov 2019 22 Oct 2019 10 Dec 2019 0.645 Tunai
14 Aug 2019 20 Jun 2019 10 Sep 2019 0.645 Tunai
16 May 2019 07 May 2019 10 Jun 2019 0.645 Tunai
14 Feb 2019 19 Dec 2018 08 Mar 2019 0.645 Tunai
14 Nov 2018 16 Oct 2018 10 Dec 2018 0.5625 Tunai
14 Aug 2018 19 Jun 2018 10 Sep 2018 0.5625 Tunai
16 May 2018 07 May 2018 08 Jun 2018 0.5625 Tunai
14 Feb 2018 11 Dec 2017 09 Mar 2018 0.5625 Tunai
14 Nov 2017 16 Oct 2017 08 Dec 2017 0.52 Tunai
11 Aug 2017 19 Jun 2017 08 Sep 2017 0.52 Tunai
11 May 2017 01 May 2017 09 Jun 2017 0.52 Tunai
13 Feb 2017 12 Dec 2016 10 Mar 2017 0.52 Tunai
10 Nov 2016 17 Oct 2016 09 Dec 2016 0.51 Tunai
11 Aug 2016 20 Jun 2016 09 Sep 2016 0.51 Tunai
11 May 2016 02 May 2016 10 Jun 2016 0.51 Tunai
10 Feb 2016 08 Dec 2015 10 Mar 2016 0.51 Tunai
10 Nov 2015 19 Oct 2015 10 Dec 2015 0.5 Tunai
12 Aug 2015 15 Jun 2015 10 Sep 2015 0.5 Tunai
14 May 2015 04 May 2015 10 Jun 2015 0.5 Tunai
11 Feb 2015 15 Dec 2014 10 Mar 2015 0.5 Tunai
12 Nov 2014 20 Oct 2014 10 Dec 2014 0.49 Tunai
13 Aug 2014 16 Jun 2014 10 Sep 2014 0.49 Tunai
13 May 2014 05 May 2014 10 Jun 2014 0.49 Tunai
12 Feb 2014 16 Dec 2013 10 Mar 2014 0.49 Tunai
13 Nov 2013 21 Oct 2013 10 Dec 2013 0.49 Tunai
13 Aug 2013 18 Jun 2013 10 Sep 2013 0.49 Tunai
14 May 2013 03 May 2013 10 Jun 2013 0.49 Tunai
13 Feb 2013 17 Dec 2012 08 Mar 2013 0.49 Tunai
13 Nov 2012 15 Oct 2012 10 Dec 2012 0.49 Tunai
13 Aug 2012 19 Jun 2012 10 Sep 2012 0.49 Tunai
13 Feb 2012 12 Dec 2011 09 Mar 2012 0.49 Tunai
10 Nov 2011 17 Oct 2011 09 Dec 2011 0.49 Tunai
11 Aug 2011 20 Jun 2011 09 Sep 2011 0.49 Tunai
11 May 2011 18 Apr 2011 10 Jun 2011 0.49 Tunai
11 Feb 2011 13 Dec 2010 10 Mar 2011 0.49 Tunai
10 Nov 2010 18 Oct 2010 10 Dec 2010 0.49 Tunai
11 Aug 2010 21 Jun 2010 10 Sep 2010 0.49 Tunai
12 May 2010 19 Apr 2010 10 Jun 2010 0.49 Tunai
10 Feb 2010 14 Dec 2009 10 Mar 2010 0.49 Tunai
10 Nov 2009 19 Oct 2009 10 Dec 2009 0.49 Tunai
12 Aug 2009 22 Jun 2009 10 Sep 2009 0.49 Tunai
13 May 2009 20 Apr 2009 10 Jun 2009 0.49 Tunai
11 Feb 2009 15 Dec 2008 10 Mar 2009 0.49 Tunai
12 Nov 2008 20 Oct 2008 10 Dec 2008 0.47 Tunai
13 Aug 2008 20 Jun 2008 10 Sep 2008 0.47 Tunai
13 Feb 2008 17 Dec 2007 10 Mar 2008 0.47 Tunai
13 Nov 2007 15 Oct 2007 10 Dec 2007 0.425 Tunai
13 Aug 2007 21 Jun 2007 10 Sep 2007 0.425 Tunai
11 May 2007 16 Apr 2007 08 Jun 2007 0.425 Tunai
13 Feb 2007 18 Dec 2006 09 Mar 2007 0.425 Tunai
13 Nov 2006 16 Oct 2006 08 Dec 2006 0.4 Tunai
11 Aug 2006 26 Jun 2006 08 Sep 2006 0.4 Tunai
11 May 2006 24 Apr 2006 09 Jun 2006 0.4 Tunai
13 Feb 2006 19 Dec 2005 10 Mar 2006 0.4 Tunai
10 Nov 2005 17 Oct 2005 09 Dec 2005 0.38 Tunai
11 Aug 2005 24 Jun 2005 09 Sep 2005 0.38 Tunai
11 May 2005 18 Apr 2005 10 Jun 2005 0.38 Tunai
11 Feb 2005 20 Dec 2004 10 Mar 2005 0.38 Tunai
10 Nov 2004 18 Oct 2004 10 Dec 2004 0.355 Tunai
11 Aug 2004 28 Jun 2004 10 Sep 2004 0.355 Tunai
12 May 2004 19 Apr 2004 10 Jun 2004 0.355 Tunai
11 Feb 2004 15 Dec 2003 10 Mar 2004 0.355 Tunai
12 Nov 2003 20 Oct 2003 10 Dec 2003 0.335 Tunai
13 Aug 2003 23 Jun 2003 10 Sep 2003 0.335 Tunai
13 May 2003 28 Apr 2003 10 Jun 2003 0.335 Tunai
12 Feb 2003 16 Dec 2002 10 Mar 2003 0.335 Tunai
13 Nov 2002 21 Oct 2002 10 Dec 2002 0.31 Tunai
13 Aug 2002 24 Jun 2002 10 Sep 2002 0.31 Tunai
13 May 2002 15 Apr 2002 10 Jun 2002 0.31 Tunai
13 Feb 2002 17 Dec 2001 08 Mar 2002 0.31 Tunai
13 Nov 2001 15 Oct 2001 10 Dec 2001 0.28 Tunai
13 Aug 2001 25 Jun 2001 10 Sep 2001 0.28 Tunai
11 May 2001 16 Apr 2001 11 Jun 2001 0.28 Tunai
13 Feb 2001 18 Dec 2000 09 Mar 2001 0.28 Tunai
13 Nov 2000 16 Oct 2000 11 Dec 2000 0.26 Tunai
11 Aug 2000 26 Jun 2000 11 Sep 2000 0.26 Tunai
11 May 2000 17 Apr 2000 09 Jun 2000 0.26 Tunai
11 Feb 2000 20 Dec 1999 10 Mar 2000 0.26 Tunai
10 Nov 1999 18 Oct 1999 10 Dec 1999 0.23 Tunai
11 Aug 1999 19 Jul 1999 10 Sep 1999 0.23 Tunai
12 May 1999 19 Apr 1999 10 Jun 1999 0.23 Tunai
10 Feb 1999 21 Dec 1998 10 Mar 1999 0.23 Tunai
10 Nov 1998 20 Oct 1998 10 Dec 1998 0.2 Tunai
12 Aug 1998 20 Jul 1998 10 Sep 1998 0.2 Tunai
13 May 1998 20 Apr 1998 10 Jun 1998 0.2 Tunai
11 Feb 1998 15 Dec 1997 10 Mar 1998 0.2 Tunai
12 Nov 1997 15 Sep 1997 10 Dec 1997 0.2 Tunai
13 Aug 1997 21 Jul 1997 10 Sep 1997 0.36 Tunai
13 May 1997 21 Apr 1997 10 Jun 1997 0.36 Tunai
12 Feb 1997 16 Dec 1996 10 Mar 1997 0.36 Tunai
13 Nov 1996 21 Oct 1996 10 Dec 1996 0.3425 Tunai
13 Aug 1996 15 Jul 1996 10 Sep 1996 0.3425 Tunai
13 May 1996 15 Apr 1996 10 Jun 1996 0.3425 Tunai
13 Feb 1996 18 Dec 1995 11 Mar 1996 0.3425 Tunai
13 Nov 1995 17 Oct 1995 11 Dec 1995 0.685 Tunai
11 Aug 1995 17 Jul 1995 11 Sep 1995 0.645 Tunai
09 May 1995 17 Apr 1995 12 Jun 1995 0.645 Tunai
Papar semua

Hasil Dividen Tahunan

Tahun Dividen Tahunan ($) Kekerapan/Tahun Hasil %
2024 5.20 4 0.65
2023 4.52 4 0.78
2022 3.92 4 1.07
2021 3.40 4 1.23
2020 2.96 4 1.75
2019 2.58 4 1.96
2018 2.25 4 1.94
2017 2.08 4 2.46
2016 2.04 4 2.77
2015 2.00 4 2.37
2014 1.96 4 2.84
2013 1.96 4 3.84
2012 1.47 3 2.98
2011 1.96 4 4.72
2010 1.96 4 5.59
2009 1.96 4 5.49
2008 1.41 3 3.50
2007 1.70 4 3.18
2006 1.60 4 3.07
2005 1.52 4 2.69
2004 1.42 4 2.50
2003 1.34 4 1.91
2002 1.24 4 1.95
2001 1.12 4 1.43
2000 1.04 4 1.12
1999 0.920 4 1.38
1998 0.800 4 0.90
1997 1.28 4 1.84
1996 1.37 4 3.75
1995 1.98 3 7.02
Papar semua

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2024 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda